Novartis Strategy: Pure Play Focus and AI Integration
Novartis CEO Vasant Narasimhan details the strategic shift to a pure-play biopharma model, unlocking $180 billion in value. The analysis covers platform technologies in cell therapy, RNA, and radioligands, alongside the operational impact of AI and global competitive dynamics.